GenFleet Therapeutics is a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, founded in 2017 by veteran drug developers with the support from top-tier venture capital investors. Dedicated to serving significant unmet medical needs, GenFleet Therapeutics established its proprietary R&D platform based on the deep understanding of disease biology, translational medicine, as well as the research into latest biological mechanism of cancer pathways, tumor microenvironment and human immunoregulation. GenFleet's rich and diversified pipeline highlights multiple cutting-edge products with novel mechanisms and global IP.
Staff with Master or Doctoral Degrees
Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates - both small molecules and biologics. Its pipeline includes over 10 programs in development, many of which have entered clinical stages.
Among them, the TGF-β R1 (transforming growth factor-β receptor 1) inhibitor is entering phase II clinical trial and boasts broad prospects of treating various solid tumors; the CDK9（cyclin-dependent kinase 9） inhibitor has been granted with IND approval in China and US, marking the beginning of the company's global multi-center clinical trial strategy；besides, GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage. In mid 2021, GenFleet also received IND approval to proceed with the clinical trials of its KRAS G12C inhibitor.
GenFleet Therapeutics and Innovent jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet's lead KRAS G12C candidate, GFH925 in China with additional option-in rights for global development and commercialization.
GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology worldwide, today announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GFH925 in a multi-center phase I / II clinical trial treating advanced solid tumors among patients with KRAS G12C gene mutation.
The agreement outlines a constructive framework where GenFleet will synergize its own R&D systems with Insilco’s end-to-end AI-powered drug discovery platform and Biortus’ structural biology platform, with a view to jointly addressing significant unmet medical needs and tackling novel & difficult targets in cancer therapeutics.